Abilify News and Research

RSS

Aripiprazole (marketed as Abilify, Abilify Discmelt) is an atypical antipsychotic medication approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.

Obecure granted patent covering betahistine with olanzapine for mitigating antipsychotic drug associated weight gain

Obecure Ltd., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., has received notice of allowance from the US Patent Office for its two key patent applications covering methods of use and compositions covering the use of betahistine with olanzapine for the mitigation of the serious weight gain associated as a side effect of the antipsychotic drug.

23 Feb 2010

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group.

17 Feb 2010

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes, Inc. today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies.

4 Feb 2010

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

2 Dec 2009

FDA approves sNDA for pediatric autism drug ABILIFY

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.

20 Nov 2009

Bipolar disorder drug market to decline from $6.3 billion to $5 billion

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that widespread generic erosion of branded atypical antipsychotics will cause the bipolar disorder drug market to decline from $6.3 billion in 2008 to approximately $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

6 Nov 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

A new treatment option for Canadians with schizophrenia, ABILIFY(TM) (aripiprazole), is now available in Canada. For those living with this lifelong disease who may be struggling with a treatment that doesn't work for them or with side effects that are difficult to tolerate, ABILIFY offers efficacy and good safety and tolerability with limited impact on weight, blood sugar and lipids - significant clinical benefits that may help patients stay on treatment longer.

6 Oct 2009

St. Petersburg Times examines decline in antipsychotic drug prescriptions for Florida children

St. Petersburg Times recently examined how since the Florida Medicaid program last year began requiring physicians to receive approval before prescribing antipsychotic drugs to children younger than age six, the number of prescriptions for children in that age group has dropped by nearly 75%, according to new data from the Florida Agency for Health Care Administration.

31 Mar 2009

Warning about use of psychiatric drugs with the elderly

Health officials in the U.S. are warning doctors that prescribing certain psychiatric drugs to elderly people suffering from dementia can increase their risk of death.

17 Jun 2008

Antipsychotic drugs get FDA label changes

The U.S. Food and Drug Administration today exercised its new authority under the Food and Drug Administration Amendments Act of 2007 (FDAAA) to require manufacturers of "conventional" antipsychotic drugs to make safety-related changes to prescribing information, or labeling, to warn about an increased risk of death associated with the off-label use of these drugs to treat behavioral problems in older people with dementia.

16 Jun 2008

Abilify (aripiprazole) approved for acute treatment of bipolar I disorder in adolescents

Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old).

1 Mar 2008

Drug to treat children with bipolar disorder gets priority review

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

15 Nov 2007

Urgent need for better understanding of bipolar disease in children and adolescents

The number of visits to a doctor's office that resulted in a diagnosis of bipolar disorder in children and adolescents has increased by 40 times over the last decade, reported researchers funded in part by the National Institutes of Health (NIH).

4 Sep 2007

Bristol-Myers Squibb and Otsuka Pharmaceutical announce availability of 2 mg Abilify (aripiprazole) tablet

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced two newly available options of Abilify (aripiprazole) -- a 2 mg tablet strength and a nonrefrigerated oral solution (1 mg/mL).

7 Feb 2006

FDA issues public health advisory for antipsychotic drugs

The Food and Drug Administration (FDA) has issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.”

12 Apr 2005

FDA wants warnings put on antipsychotic drugs

The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of “atypical antipsychotic drugs.”

11 Apr 2005

Approval of Abilify (aripiprazole) for the treatment of acute bipolar mania

Bristol-Myers Squibb and Otsuka Pharmaceutical have announced that the U.S. Food and Drug Administration (FDA) has approved Abilify (aripiprazole) for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder.

4 Oct 2004

New and Generic Drug Approvals from FDA

This newly approved or tentatively approved drug listing from the FDA is an interim page intended to provide timely information on new drug products as a more comprehensive page is developed.

12 Apr 2004